DUBLIN–(BUSINESS WIRE)–June 10, 2022–
The “Blood and Plasma Components Market – A Global and Regional Analysis: Focus on Product, Application, End-User and Region – Analysis and Forecast, 2021-2031” report has been added to ResearchAndMarkets’ offering. .com.
The global blood and plasma components market is expected to reach USD 66.47 billion in 2031 from USD 39.58 billion in 2020, growing at a CAGR of 4.90% during the forecast period 2021-2031.
The global blood and plasma components market is expected to witness minimal growth, owing to the growing burden of primary immunodeficiency diseases such as hemophilia A, von Willebrand disease (vWD) and secondary immunodeficiency diseases.
Additionally, the growing burden of cancer, hematological malignancies, and organ transplantation are also contributing to the growth of the market. An increase in research and development on the use of plasma components for the treatment of neurological disorders such as chronic inflammatory demyelinating polyneuropathy (CIDP) is also driving the growth of the market.
Moreover, the initiatives taken by the major players in the global blood and plasma components market to expand and launch more blood and plasma collection centers across the globe to cater the supply of blood and plasma components are the major factors that are expected to fuel the growth of the market.
The global blood and plasma components market includes well-established companies along with a few emerging ones. Several companies in the global blood and plasma components market are trying to expand their presence in the market by undertaking business expansion activities such as launching new blood and plasma collection centers in new locations.
In addition, companies are constantly working on research and development to expand the indications of plasma-derived products already on the market. The major players in the global blood and plasma components market witnessed major business expansion, product approvals, and synergistic activities in the market during the period January 2018-January 2022.
The inclination of companies towards product approvals, synergistic activities and business expansion activities suggests that companies are constantly striving to explore the potential of blood and plasma components for new application areas and to offer products to meet the growing demand for blood and plasma components.
Key Questions Answered by the Report
- How are blood and plasma components revolutionizing the landscape of hematology and solid tumor management?
- What are the key market drivers, challenges and opportunities in the Global Blood and Plasma Components Market?
- What are the underlying structures resulting from the emerging trends in the global blood and plasma components market?
- What has been the impact of the COVID-19 pandemic on the global blood and plasma component ecosystem?
- What are the key development strategies implemented by the major players to stay in the competitive market?
- What are the main regulatory implications in developed and developing regions regarding the use of blood and plasma components?
- What are the potential entry barriers faced by companies wishing to enter a particular market region?
- What will be the growth rate of the global blood and plasma components market during the forecast period?
- How is each segment of the market expected to grow during the forecast period 2021-2031 and what revenue is expected to be generated by each of the segments?
- What are the growth opportunities for blood and plasma component companies in their region of operation?
- Who are the leading players with major deals in the Global Blood and Plasma Components Market?
- Which companies are expected to be highly disruptive in the future, and why?
Main topics covered:
1.1 Product Definition
1.1.1 Inclusion and exclusion criteria
1.2 Market Scope
1.2.1 Scope of the study
1.2.2 Key questions answered by the report
1.3 Research methodology
1.3.1 Global Blood and Plasma Components Market: Research Methodology
1.3.2 Data sources
184.108.40.206 Primary data sources
220.127.116.11 Secondary data sources
1.3.3 Market estimation model
1.3.4 Business profiling criteria
1.4 Market Overview
1.4.1 Red blood cells
1.5 Historical trends in the use of blood components
1.6 Use of blood components
1.7 Market Footprint and Future Potential, USD Million, 2020-2031
2 Industry Analysis
2.2 Regulatory framework
2.2.1 Regulatory framework in the United States
2.2.2 Regulatory framework in the European Union
2.2.3 Regulatory framework in Asia-Pacific
2.3 Supply Chain Analysis
2.4 Impact of COVID-19 on the Global Blood and Plasma Components Market
3 Market dynamics
3.2 Impact analysis
3.3 Market Drivers
3.3.1 Global Increase in Patients with Blood Disorders
3.3.2 Increase in the number of trauma patients and chronic illnesses
3.3.3 Increased number of product launches and approvals
3.4 Market Constraints
3.4.1 Risk of infectious diseases transmitted by transfusion and adverse effects associated with blood transfusion
3.4.2 Long duration of the manufacturing process and strict regulatory guidelines
3.5 Market opportunities
3.5.1 Increased adoption of business expansion strategies in the market
4 Competitive landscape
4.2 Business Strategies
4.2.1 Mergers and Acquisitions
4.2.2 Synergistic Activities
4.2.3 Business expansion, funding and reimbursement activities
4.3 Business Strategies
4.3.1 Product launches
4.3.2 Product Approvals
4.4 Market Share Analysis, by Company (2020)
4.5 Growth Share Analysis
5 products, million dollars, 2020-2031
5.2 Transfusion market
5.2.1 Concentrated red blood cells
5.2.2 Platelet products
5.2.3 Frozen plasma
5.3 Plasma-derived products
18.104.22.168 Intravenous immunoglobulins
22.214.171.124 Subcutaneous immunoglobulins
126.96.36.199 Other immunoglobulins
5.3.2 Clotting factor concentrates
188.8.131.52 Coagulation factor VIII concentrate
184.108.40.206 Coagulation factor IX concentrate
220.127.116.11 Von Willebrand Factor (vWF)
18.104.22.168 Prothrombin complex concentrates
22.214.171.124 Clotting factor XIII concentrate
5.3.4 Proteinase inhibitors
5.3.5 Other blood derivatives
6 Demand, USD million, 2020-2031
126.96.36.199 Sickle cell disease
188.8.131.52 Platelet refractory
6.2.2 Management of hematological malignancies
184.108.40.206 Von Willebrand disease
6.3 Management of solid tumors
6.5 Emerging fields of application
7 end users, billions of dollars, 2020-2031
7.2 Hospitals and specialized clinics
7.3 Research institutions
7.4 Diagnostic laboratories
7.5 Other end users
8 Region, millions of dollars, 2020-2031
8.2 North America
8.2.1 United States
8.3.2 United Kingdom
8.3.6 Rest of Europe
8.4.5 South Korea
8.4.7 Rest of Asia-Pacific
8.5 Rest of the world
9 Market – Competitive Benchmarking and Company Profiles
- CSL Limited
- Grifols, SA
- ADMA Biologics, Inc.
- Takeda Pharmaceutical Company Limited
- Octapharma AG
- Kedrion SpA
- Emergent BioSolutions Inc.
- Organic Products Laboratory Ltd.
- LFB SA
- American Red Cross
- Versiti, Inc.
- Blood Centers of America
- Carter BloodCare
- Memorial Blood Centers
For more information about this report visit https://www.researchandmarkets.com/r/nhs0vi
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220610005254/en/
Laura Wood, Senior Press Officer
For EST business hours, call 1-917-300-0470
For US/CAN call toll free 1-800-526-8630
For GMT office hours call +353-1-416-8900
SECTOR KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH
SOURCE: Research and Markets
Copyright BusinessWire 2022.
PUBLISHED: 06/10/2022 06:45 AM/DISC: 06/10/2022 06:47 AM